Lower Cancer Metastasis Rates in GLP-1 Users
Five-Year Survival Rate Also Higher Than Non-Users

Recent research has found that GLP-1 class obesity and diabetes treatments, such as Wegovy and Mounjaro, may improve treatment outcomes for cancer patients.


On May 21 (local time), the Wall Street Journal (WSJ) reported the results of a study led by researchers at the Cleveland Clinic Cancer Center. The research team tracked more than 10,000 patients who began taking GLP-1 medications after being diagnosed with early-stage cancer and compared their disease progression to that of patients taking other diabetes medications. The results showed that the group taking GLP-1 drugs had a lower probability of cancer metastasis than the comparison group.

Novo Nordisk's GLP-1 class treatment 'Wegovy' (active ingredient semaglutide). Novo Nordisk

Novo Nordisk's GLP-1 class treatment 'Wegovy' (active ingredient semaglutide). Novo Nordisk

View original image

For lung cancer patients, the rate of progression to advanced disease (when the disease spreads beyond the early stage to surrounding tissues or other organs) was less than half in the GLP-1 group (10%) compared to the control group (22%). A similar pattern was observed in breast cancer patients, with the GLP-1 group at around 10% and the control group at 20%. Statistically significant reductions were also seen for colorectal and liver cancers.


Mark Orland, a resident at the Cleveland Clinic, emphasized, "Millions of Americans are taking GLP-1 medications. It is extremely important for us to immediately understand what potential anti-tumor effects these drugs may have."


There are other studies on the five-year survival rate for people taking GLP-1 medications. According to a paper from the University of Texas MD Anderson Cancer Center, which analyzed over 137,000 breast cancer patients, those taking GLP-1 drugs had a five-year survival rate of over 95%, higher than non-users (89.5%). Dr. Jasmine Sukumar, a breast oncologist at MD Anderson Cancer Center who participated in the study, explained, "We are seeing this trend appear in a variety of databases."

Mounza injection used for weight loss procedures at a clinic in Mumbai, India. Photo by Reuters, Yonhap News Agency

Mounza injection used for weight loss procedures at a clinic in Mumbai, India. Photo by Reuters, Yonhap News Agency

View original image

A University of Pennsylvania study of about 95,000 women who underwent breast imaging found that, even after accounting for other risk factors such as age and weight, women who took GLP-1 medications had about a 25% lower probability of being diagnosed with breast cancer.


There are several hypotheses as to why GLP-1 drugs may appear to be effective against cancer. Some suggest that weight loss and improved metabolic health indirectly reduce cancer risk. Others propose that, since GLP-1 receptors are expressed on the surface of some cancer cells, these drugs might have a more direct effect on the biological mechanisms of cancer.



However, these studies are limited in that they are observational studies based on retrospective review, not clinical trials. In particular, patients prescribed GLP-1 medications tend to have better access to medical care and receive more consistent follow-up management than those who do not, which could have contributed to better outcomes. It is also known that Novo Nordisk, which manufactures Wegovy, and Eli Lilly, the manufacturer of Mounjaro, are not currently studying the anti-cancer effects of these drugs.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing